Therapeutic Area

Oncology

Corcept is committed to investigating the role of selective GR antagonists (SGRAs) with clinical studies in solid tumors. This site contains scientific resources and information developed or curated by Corcept for healthcare professionals.

2026

Poster

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress

2026

Poster

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress

2026

Poster

SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

American Society of Clinical Oncology (ASCO) Annual Meeting

2026

2025

Presentation

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

International Gynecologic Cancer Society (IGCS) Annual Global Meeting

2025

Presentation

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

European Society for Medical Oncology (ESMO) Congress

2025

Poster

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

European Society for Medical Oncology (ESMO) Congress

2025

2024

Poster

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Society of Gynecologic Oncology (SGO) Annual Meeting

2024

2023

Poster

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab-paclitaxel vs. Nab-paclitaxel in Platinum-Resistant Ovarian Cancer

International Gynecologic Cancer Society (IGCS) Annual Global Meeting

2023

Poster

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

European Society of Gynaecological Oncology (ESGO) Congress

2023

Presentation

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

American Association for Cancer Research (AACR) Annual Meeting

2023

2022

Poster

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

International Gynecologic Cancer Society (IGCS) Annual Global Meeting

2022

Presentation

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

European Society for Medical Oncology (ESMO) Congress

2022

Poster

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

European Society for Medical Oncology (ESMO) Congress

2022

2021

Presentation

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

European Society for Medical Oncology (ESMO) Congress

2021

2020

Poster

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

American Association for Cancer Research (AACR) Annual Meeting

2020

Poster

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol

American Society of Clinical Oncology (ASCO) Annual Meeting

2020

2019

Poster

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

2019

2013

Poster

A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

San Antonio Breast Cancer Symposium (SABCS)

2013

Publication

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

2026

Publication

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

2026

Publication

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

2025

Publication

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

2025

Publication

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

2023

Publication

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

2023

Publication

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

2023

Publication

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

2022

Publication

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

2022

Publication

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

2021

Publication

Adrenal tumors provide insight into the role of cortisol in NK cell activity

2021

Publication

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth

2017

Publication

The biology of hormone refractory prostate cancer. Why does it develop?

1999

Publication

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer

2013

Publication

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma

2015

Publication

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer

2014

Publication

Minireview: nuclear receptors and breast cancer

2008

Publication

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers

2011

Publication

Steroid receptors aplenty in prostate cancer

2014

Publication

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay

2017

Publication

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer

2015

Publication

Mifepristone inhibits GRβ coupled prostate cancer proliferation

2012

Publication

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression

2011

Publication

Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer

2008

Publication

Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro

2008

Publication

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

2016

Publication

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

2017

Publication

Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues

2009

Mechanism of Action Resource

Relacorilant: Mechanism of Action

Mechanism of Disease Resource

From Stress Signaling to Therapeutic Opportunity: Explore the Role of Cortisol in Cancer Therapy Resistance

Resource

Compassionate Use

Resource

Oncology

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab-paclitaxel vs. Nab-paclitaxel in Platinum-Resistant Ovarian Cancer

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth

The biology of hormone refractory prostate cancer. Why does it develop?

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer

Minireview: nuclear receptors and breast cancer

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers

Steroid receptors aplenty in prostate cancer

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer

Mifepristone inhibits GRβ coupled prostate cancer proliferation

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression

Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer

Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues

Relacorilant: Mechanism of Action

From Stress Signaling to Therapeutic Opportunity: Explore the Role of Cortisol in Cancer Therapy Resistance

Compassionate Use

Medical Education Grants

You are leaving Corcept Medical

Search

Search